$AEMD To Present Clinical Study Results at The BIO International Convention

SAN DIEGO, June 14, 2017  — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that Company Chairman and CEO, Jim Joyce will present at the 2017 BIO International Convention (BIO 2017) on June 21, 2017 at 11:15 AM Pacific Time. BIO 2107, which is being held at the San Diego Convention Center, attracts more than 16,000 biotechnology industry executives from 76 countries. Mr. Joyce will present virus capture data from a recently concluded FDA-approved feasibility study that was designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals infected with a viral pathogen.

The presentation will be live audio webcast through a link available in the upcoming events section of the company’s website at https://www.aethlonmedical.com/news-media/events.

The Aethlon Hemopurifier® is a first-in-class medical device designed for the single-use removal of viral pathogens from the circulatory system of infected individuals.

The Hemopurifier® is a candidate treatment countermeasure to address a broad-spectrum of viruses that are not addressed with antiviral drug therapies, including natural occurring pandemic threats and agents of bioterrorism.  Additionally, the device provides a strategy to augment the benefit of approved antiviral drug regimens.

Aethlon believes the Hemopurifier® can achieve the U.S. Government’s broad-spectrum treatment goal against emerging viral threats. More specifically, the Company is advancing the Hemopurifer® to fulfill the U.S. Department of Health and Human Services (HHS) initiative to manufacture and procure medical countermeasures, including non-pharmaceutical therapies, that can address multiple high-priority bioterror and pandemic threats, yet may also have commercial viability in other markets. To date, the Hemopurifier® has been validated to capture 16 different viral threats and has been the subject of multiple human studies. .

About Aethlon Medical, Inc.

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body’s natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals.  The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism.  The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens.  At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study.  Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer’s disease (AD) and Chronic Traumatic Encephalopathy (CTE).  ESI’s TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company’s ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, including any diagnostic products, that the FDA will not approve the initiation or continuation of the Company’s clinical programs or provide market clearance of the Company’s products, including clearance through  the 21st Century Cures Act, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company’s other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:

Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

Investor Relations:

John Marco
CORE IR
516 222 2560
johnm@coreir.com